FBIO - コロナド・バイオサイエンシズ (Fortress Biotech Inc.) コロナド・バイオサイエンシズ

 FBIOのチャート


 FBIOの企業情報

symbol FBIO
会社名 Fortress Biotech Inc (コロナド・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 フォートレス・バイオテック(Fortress Biotech Inc.) は新規医薬品バイオテクノロジー製品を取得、開発、および商業化するバイオ医薬品会社である。特定の子会社を通じて製品を開発し、商品化する。Fortressには、免疫腫瘍学、血液学、遺伝子治療、疼痛管理、希少疾患及び皮膚科の6つの治療領域を対象とした、4つの商業ステージプログラム、25の開発ステージプログラムを含む11の事業子会社がある。Fortressは、内部開発プログラムに加えて、バイオ医薬ビジネスの専門知識と医薬品開発能力を活用し、Fortress Companiesを支援するための資金調達と管理サービスを提供する。同社の子会社には、Aevitas Therapeutics Avenue Therapeutics Caelum Biosciences Cellvation Inc. Checkpoint Therapeutics Cyprium Therapeutics Helocyte Inc. Journey Medical Corporation Mustang Bio National Holdings Corp 及び Tamid Bio Inc.を含む。   コロナド・バイオサイエンシズは、米国の生物学的薬剤メ―カ―。自己免疫疾患および癌の治療のための免疫療法と薬剤の開発に焦点を当てる。臨床開発段階の主要な製品候補は、クロ―ン病、潰瘍性大腸炎、多発性硬化症などの自己免疫疾患の治療向けCNDO-201、急性骨髄性白血病の治療向けCNDO-109。   Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest- growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high- potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital and Nationwide Children's Hospital.
本社所在地 2 Gansevoort Street 9th Floor New York NY 10014 USA
代表者氏名 Lindsay A. Rosenwald Lindsay A. Rosenwald
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 781-652-4500
設立年月日 38869
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 45人
url www.fortressbiotech.com
nasdaq_url https://www.nasdaq.com/symbol/fbio
adr_tso
EBITDA EBITDA(百万ドル) -117.12600
終値(lastsale) 1.37
時価総額(marketcap) 74449346.93
時価総額 時価総額(百万ドル) 52.44603
売上高 売上高(百万ドル) 211.46400
企業価値(EV) 企業価値(EV)(百万ドル) -0.92697
当期純利益 当期純利益(百万ドル) -37.95800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Fortress Biotech Inc revenues increased 25% to $119.3M. Net loss increased 45% to $42.6M. Revenues reflect National segment increase of 21% to $106.5M Dermatology Product segment increase of 99% to $12.2M. Higher net loss reflects Research and developement increase from $15.6M to $39.3M (expense) Total National operating expenses increase of 17% to $107.1M (expense).

 FBIOのテクニカル分析


 FBIOのニュース

   Dr. Reddy''s Lab, Fortress Biotech Ink DFD-29 Collaboration Pact For Chronic Skin Disorder  2021/06/30 15:29:53 Benzinga
Journey Medical Corporation , a partner company of Fortress Biotech Inc (NASDAQ: FBIO ), has entered into a collaborative development and commercialization agreement with Dr. Reddy''s Laboratories Ltd (NYSE: RDY ) for the DFD-29 (Minocycline Modified Release Capsules 40 mg) for the treatment of rosacea. Journey Medical has acquired global commercialization rights, including the Full story available on Benzinga.com
   Journey Medical Partners Dr. Reddy''s To Develop DFD-29 To Treat Rosacea  2021/06/30 13:34:00 FinanzNachrichten
NEW DELHI (dpa-AFX) - Journey Medical Corp., a partner company of biopharmaceutical company Fortress Biotech, Inc. (FBIO), announced Wednesday an agreement with India-based pharmaceutical company
   Journey Medical Partners Dr. Reddy''s To Develop DFD-29 To Treat Rosacea - Quick Facts  2021/06/30 13:13:10 Business Insider Markets
(RTTNews) - Journey Medical Corp., a partner company of biopharmaceutical company Fortress Biotech, Inc. (FBIO), announced Wednesday an agreement with India-based pharmaceutical company Dr. Reddy''s Laboratories Ltd. (RDY) for the collaborative development and commercialization of the DFD-29 program (Minocycline Modified Release Capsules 40 mg)
   Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy''s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea  2021/06/30 12:00:00 Benzinga
NEW YORK and SCOTTSDALE, Ariz., June 30, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical"), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO ) ("Fortress"), today announced an agreement with Dr. Reddy''s Laboratories Ltd. ("Dr. Reddy''s") for the collaborative development and commercialization of the DFD-29 program (Minocycline Modified Release Capsules 40 mg) for the treatment of rosacea. Journey Medical has acquired global commercialization rights including the U.S. and Europe, except that Dr. Reddy''s has retained certain rights to the program in select markets including Brazil, Russia, India and China. Through this collaboration, the parties will work together to complete the development of DFD-29. Dr. Reddy''s will provide development support including the monitoring of two Phase 3 clinical trials. A Phase 2 study in Germany was completed which assessed the efficacy, safety and tolerability of DFD-29 for the treatment of inflammatory lesions of rosacea over 16 weeks.
   Hedge Funds Are Selling Fortress Biotech Inc (FBIO)  2021/06/28 17:04:35 Insider Monkey
   Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly  2021/04/06 13:07:55 Benzinga
The following article is sponsored by Actinium Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. As science advances in terms of finding new treatments for unmet medical needs, certain approaches are not appropriate for specific types of patients. For example, when it comes to older patients, often certain treatments can be counterproductive, leaving them vulnerable and without a way to combat the disease. In the biotech world, many are racing to give people solutions and hope for a better future. While we are ages from having prompt answers, companies like Fortress Biotech, Inc. (NASDAQ: FBIO ), Viking Therapeutics (NASDAQ: VKTX ), Onconova Therapeutics (NASDAQ: ONTX ), Fusion Pharmaceuticals Inc (NASDAQ: FUSN ), Gilead Sciences, Inc. (NASDAQ: GILD ) and Bristol-Myers Squibb (NYSE: BMY ), among others, are on the front lines of this race.
   Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition  2021/04/01 13:02:28 Benzinga
Fortress Biotech Inc's (NASDAQ: FBIO ) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc , a wholly-owned subsidiary of Eli Lilly And Co (NYSE: LLY ). The transaction … Full story available on Benzinga.com
   Fortress Biotech CEO Explains The Company's Three-Step Business Model  2021/02/23 14:08:13 Benzinga
Fortress Biotech was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Companies within the fields of biotechnology and pharmaceuticals work to develop medicines for the treatment of various diseases and medical conditions. Typically, companies in both industries tend to focus their research on a specific branch of medicine (i.e., oncology, immunology, neurology, etc.). And while most pharmaceutical and biotech companies focus solely on developing their own programs, Fortress Biotech (NASDAQ: FBIO ) takes a different approach to this classic business model. Fortress Biotech is a biopharmaceutical company that focuses on identifying promising drug candidates. Once identified, the company acquires, develops, and markets these assets with the help of its partner companies and collaborations with academic research institutions.
   DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm  2021/01/25 14:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc.
   FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class Action - FBIO  2021/01/23 20:16:06 MarketScreener
NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. between December 11, 2019 and October…
   Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly  2021/04/06 13:07:55 Benzinga
The following article is sponsored by Actinium Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. As science advances in terms of finding new treatments for unmet medical needs, certain approaches are not appropriate for specific types of patients. For example, when it comes to older patients, often certain treatments can be counterproductive, leaving them vulnerable and without a way to combat the disease. In the biotech world, many are racing to give people solutions and hope for a better future. While we are ages from having prompt answers, companies like Fortress Biotech, Inc. (NASDAQ: FBIO ), Viking Therapeutics (NASDAQ: VKTX ), Onconova Therapeutics (NASDAQ: ONTX ), Fusion Pharmaceuticals Inc (NASDAQ: FUSN ), Gilead Sciences, Inc. (NASDAQ: GILD ) and Bristol-Myers Squibb (NYSE: BMY ), among others, are on the front lines of this race.
   Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition  2021/04/01 13:02:28 Benzinga
Fortress Biotech Inc's (NASDAQ: FBIO ) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc , a wholly-owned subsidiary of Eli Lilly And Co (NYSE: LLY ). The transaction … Full story available on Benzinga.com
   Fortress Biotech CEO Explains The Company's Three-Step Business Model  2021/02/23 14:08:13 Benzinga
Fortress Biotech was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Companies within the fields of biotechnology and pharmaceuticals work to develop medicines for the treatment of various diseases and medical conditions. Typically, companies in both industries tend to focus their research on a specific branch of medicine (i.e., oncology, immunology, neurology, etc.). And while most pharmaceutical and biotech companies focus solely on developing their own programs, Fortress Biotech (NASDAQ: FBIO ) takes a different approach to this classic business model. Fortress Biotech is a biopharmaceutical company that focuses on identifying promising drug candidates. Once identified, the company acquires, develops, and markets these assets with the help of its partner companies and collaborations with academic research institutions.
   DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm  2021/01/25 14:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc.
   FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class Action - FBIO  2021/01/23 20:16:06 MarketScreener
NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. between December 11, 2019 and October…

 関連キーワード  (医薬品 米国株 コロナド・バイオサイエンシズ FBIO Fortress Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)